Novel Platelet Inhibitors

Annual Review of Medicine - Tập 52 Số 1 - Trang 161-184 - 2001
Joel Bennett1
1Hematology-Oncology Division, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Tóm tắt

▪ Abstract  Platelet-inhibitory drugs are of proven benefit to individuals who suffer from atherosclerotic cardiovascular disease. Despite substantial effort to identify more potent platelet-inhibitory agents, aspirin, an irreversible inhibitor of platelet cyclooxygenase activity, remains the standard against which other drugs are judged. Drugs that appear to be at least as efficacious as aspirin in specific clinical settings include the thienopyridines ticlopidine and clopidogrel, specific inhibitors of ADP-stimulated platelet function, and the phosphodiesterase 3 inhibitor cilostazol. Ligand binding to the platelet integrin αIIbβ3 (GPIIb-IIIa), a prerequisite for platelet thrombus formation, has been a prominent target for drug development. Currently, three types of αIIbβ3 antagonists are available: the monoclonal antibody Fab fragment abciximab, cyclic peptides based on the Arg-Gly-Asp (RGD) or related amino acid motifs, and RGD-based peptidomimetics. The efficacy of each type of αIIbβ3 antagonist in the setting of acute coronary artery disease has been confirmed in multicenter clinical trials.

Từ khóa


Tài liệu tham khảo

Sixma JJ, 1977, Semin. Hematol., 14, 265

10.1056/NEJM199506083322306

Hemler ME, 1988, J. Biol. Chem., 263, 7660, 10.1016/S0021-9258(18)68549-7

10.1182/blood.V65.4.823.823

10.1182/blood.V61.1.99.99

10.1172/JCI110946

10.1097/00062752-199704050-00005

10.1016/S0092-8674(00)81607-4

10.1074/jbc.274.41.29019

10.1172/JCI114318

10.1038/318470a0

10.1111/j.1365-2141.1995.tb08900.x

10.1016/1050-1738(95)00126-3

10.1038/29325

10.1172/JCI6042

10.1172/JCI115592

10.1172/JCI115721

10.1074/jbc.273.4.2024

10.1074/jbc.273.4.2030

10.1073/pnas.95.14.8070

Kehrel B, 1998, Blood, 91, 491, 10.1182/blood.V91.2.491

10.1016/S0960-9822(99)80063-3

10.1074/jbc.274.41.29108

10.1074/jbc.275.3.1763

Brass LF. 1995. Molecular basis for platelet activation. InHematology: Basic Principles and Practice, ed. R Hoffman, EJ Benz Jr, SJ Shattil, et al, pp. 1536–51. New York: Churchill Livingstone

10.1074/jbc.271.52.33157

10.1038/349617a0

Hourani SM, 1991, Pharmacol. Rev., 43, 243

10.1042/bj2330083

10.1042/bj2920617

10.1096/fasebj.2.11.2840317

10.1016/S0006-2952(99)00346-9

Nguyen BL, 1991, Am. J. Physiol., 261, H1043

10.1055/s-0037-1614384

10.1021/bi00303a028

Gartner TK, 1985, J. Biol. Chem., 260, 11891, 10.1016/S0021-9258(17)38962-7

Bennett JS, 1988, J. Biol. Chem., 263, 12948, 10.1016/S0021-9258(18)37654-3

10.1172/JCI108841

10.1073/pnas.91.23.10938

10.1126/science.272.5267.1495

10.1172/JCI119397

10.1056/NEJM199405053301808

10.1093/ajcp/94.3.292

10.1056/NEJM199110173251605

10.1016/0140-6736(90)92336-G

1988, Lancet, 2, 349

10.1136/bmj.308.6921.81

10.1136/bmj.296.6618.313

10.1056/NEJM198907203210301

Ridker PM, Ann. Intern. Med., 1991, 835

10.1161/01.CIR.84.4.1568

RAPT Investigators. 1994. Coronary heart disease/thrombolysis/lipids: randomized trial of ridogrel, a combined thromboxane A2synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction: the ridogrel versus aspirin patency trial (RAPT).Circulation89:588–95

10.1161/01.ATV.19.10.2281

10.1016/S0014-2999(98)00305-7

10.1161/01.ATV.19.8.2007

10.2165/00003495-199550010-00002

10.1161/01.CIR.100.15.1667

10.1161/01.CIR.82.1.17

10.1016/S0140-6736(89)92327-1

10.1177/1358863X9600100210

10.1056/NEJM198908243210804

10.1056/NEJM199712113372404

10.1056/NEJM199604253341702

10.1056/NEJM199812033392303

10.1161/01.CIR.95.5.1145

10.1007/s002770050369

10.1001/archinte.159.21.2524

10.1001/jama.281.9.806

10.7326/0003-4819-128-7-199804010-00004

10.1161/01.CIR.99.2.248

10.1016/S0140-6736(96)09457-3

10.1023/A:1008981408216

10.1161/01.CIR.99.18.2364

10.1161/01.CIR.101.6.590

10.1016/S0735-1097(99)00442-8

10.1016/S0735-1097(99)00443-X

10.1056/NEJM200006153422402

10.1056/NEJM198705143162005

10.1016/S0022-510X(96)00308-5

10.1055/s-0037-1615863

10.1016/S0741-5214(98)70357-X

10.1001/archinte.159.17.2041

10.1161/01.CIR.98.7.678

10.1056/NEJM199812173392503

10.1016/S0002-9149(99)00579-2

10.1016/S0002-9149(99)00368-9

10.1172/JCI119294

10.1038/12447

10.1172/JCI1753

Marcus AJ, 1999, Blood, 94, 368a, 10.1182/blood.V94.1.368.413a47_368_371

10.1021/jm960455s

10.1073/pnas.96.22.12257

10.1093/oxfordjournals.jbchem.a022419

10.1172/JCI111931

10.1055/s-0037-1615850

10.1161/01.CIR.90.4.1757

10.1161/01.CIR.77.3.670

10.1016/S0002-9149(99)00084-3

10.1161/01.CIR.97.17.1680

10.1056/NEJM199404073301402

10.1016/S0140-6736(96)10452-9

10.1056/NEJM199905273402103

10.1056/NEJM199706123362401

10.1016/S0140-6736(98)06113-3

10.1056/NEJM199907293410503

10.1016/S0140-6736(99)10018-7

10.1161/01.CIR.100.25.2477

10.1067/mhj.2000.103743

10.1161/01.CIR.98.11.1085

10.1161/01.CIR.98.24.2695

10.1053/hj.1999.v138.a100465

10.1161/01.CIR.95.4.809

10.1182/blood.V94.2.587

10.1053/hj.1999.v138.99236

10.1016/S0002-9149(97)00572-9

10.1016/S0002-9149(99)80345-2

10.1161/01.CIR.96.5.1488

10.1016/S0002-9149(97)00575-4

10.1016/S0140-6736(96)10172-0

Deleted in proof

10.1111/j.1527-3466.1999.tb00015.x

10.1021/jm00042a007

10.1161/01.CIR.96.5.1445

10.1016/S0735-1097(98)00192-2

10.1056/NEJM199805213382103

10.1016/S0140-6736(99)10285-X

10.1056/NEJM199805213382102

10.1016/S0002-8703(98)70238-8

10.1053/hj.1999.v138.99080

10.1016/S0140-6736(99)11179-6

10.1056/NEJM200005043421803

10.1161/01.CIR.100.6.570

Thông tin
Thông tin xuất bản

Annual Review of Medicine

Tập 52 Số 1

161-184

Thông tin tác giả